INTS - סך החוב של החברה Intensity Tx

Intensity Therapeutics develops immunotherapy to combat oncology using a direct-impact method on the disease focus. The GURU.Markets website contains total debt volumes, where 0.00 serves as the base parameter value. These liabilities correlate with the implementation efficiency of the INT230-6 drug and plans to scale clinical trials against solid tumors in the US.

This indicator measures the aggregate volume of credit obligations, allowing for an assessment of the business's financial resilience to external shocks and the efficiency of its tax shield utilization. By analyzing the debt history, an investor can see how the debt load correlates with the costs of retaining a unique staff of R&D specialists, which confirms the ability of Intensity Therapeutics (INTS) to finance the development of its human capital without a critical risk of default.